SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS)
today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis,
will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 4:00 P.M. Eastern Time at the
Intercontinental Barclay Hotel in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay will be archived on the "Calendar of Events" page in the
Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of hematologic and solid
cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The
Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its
oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is
currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have
progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs,
including Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission
planned in 2019, and the Takeda-partnered pan-RAF inhibitor TAK-580, which is in a clinical trial for pediatric low-grade
glioma. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the
AKT, PKC, RSK and SGK families. Sunesis is also seeking a partner to fund the completion of development for vosaroxin, a Phase 3
investigational product for relapsed or refractory AML.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
Maeve Conneighton
Argot Partners
212-600-1902 |
Willie Quinn
Sunesis Pharmaceuticals Inc.
650-266-3716 |